LifeMD (LFMD) Set to Announce Quarterly Earnings on Wednesday

LifeMD (NASDAQ:LFMD) will issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. LifeMD has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $44.14 million for the quarter, compared to analysts’ expectations of $42.66 million. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Stock Down 1.3 %

LFMD traded down $0.08 during trading hours on Tuesday, hitting $5.90. 246,090 shares of the company’s stock were exchanged, compared to its average volume of 839,275. LifeMD has a 12-month low of $3.45 and a 12-month high of $12.88. The firm has a 50 day moving average of $7.12 and a 200 day moving average of $8.16. The firm has a market cap of $246.37 million, a P/E ratio of -8.08 and a beta of 1.24. The company has a current ratio of 0.99, a quick ratio of 0.94 and a debt-to-equity ratio of 10.83.

Analysts Set New Price Targets

Several research analysts have commented on LFMD shares. B. Riley reiterated a “buy” rating and set a $12.00 price target on shares of LifeMD in a report on Tuesday, May 21st. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of LifeMD in a report on Friday, May 10th. Cantor Fitzgerald upped their target price on shares of LifeMD from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, May 9th. KeyCorp lowered their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, BTIG Research upped their target price on shares of LifeMD from $13.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, April 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.17.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.